Svb Leerink started coverage on shares of Hookipa Pharma (NASDAQ:HOOK) in a research report released on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $20.00 target price on the stock.
Other equities research analysts have also issued research reports about the stock. Bank of America started coverage on shares of Hookipa Pharma in a research note on Monday. They issued a buy rating and a $17.00 target price on the stock. Royal Bank of Canada started coverage on shares of Hookipa Pharma in a research note on Monday. They issued an outperform rating and a $23.00 target price on the stock.
Shares of HOOK stock opened at $13.25 on Monday. Hookipa Pharma has a 12 month low of $12.62 and a 12 month high of $14.76.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Recommended Story: Why is total return important?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.